Balyasny Asset Management
ATYR

Balyasny Asset Management’s aTyr Pharma ATYR Stock Holding History

Balyasny Asset Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$72.1K – 3644
2025
Q3 		$72.1K Buy
+100,000
New +$453K ﹤0.01% 2807

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's ATYR Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in aTyr Pharma (ATYR) in Q1 2026: 10,330 shares worth $8.06K. The stake represents ﹤0.01% of the portfolio and ranks #2799 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ATYR as recently as Q1 2025.

Balyasny Asset Management first reported a position in ATYR in Q4 2024 and has held it in 3 quarters since. The position peaked at $686K in Q1 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

  • Balyasny Asset Management held 10,330 shares of aTyr Pharma worth $8.06K as of Q1 2026.
  • aTyr Pharma was a new Balyasny Asset Management position in Q1 2026.
  • aTyr Pharma made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2799 holding.
  • Balyasny Asset Management first reported a position in aTyr Pharma in Q4 2024 and has held it in 3 quarters since.
  • Balyasny Asset Management's aTyr Pharma position peaked at $686K in Q1 2025.
  • 111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.